KPV vs Vasoactive Intestinal Peptide (VIP)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
KPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profileVasoactive Intestinal Peptide (VIP)
28-amino acid neuropeptide found throughout the CNS, gut, and immune system. Functions as a potent anti-inflammatory, vasodilator, and neurotrophic factor. Research applications include CIRS (Chronic Inflammatory Response Syndrome), pulmonary arterial hypertension, autoimmune conditions, and gut motility disorders. Intranasal administration is most studied for CIRS and neuroinflammatory conditions.
Full profile| KPV | Vasoactive Intestinal Peptide (VIP) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide | VIP, vasoactive intestinal polypeptide, PHM-27 |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 250mcg–1000mcg mcg, Once or twice daily | 25mcg–100mcg mcg, Daily intranasal or 1–2x weekly subcutaneous |
| Administration | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal | Intranasal spray, Subcutaneous injection, Inhalation (nebulized) |
| Key side effects | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) | Facial flushing, Transient hypotension, Nasal irritation (intranasal route), Tachycardia |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: KPV is research-stage, while Vasoactive Intestinal Peptide (VIP) is investigational (in trials).
- Administration: KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal; Vasoactive Intestinal Peptide (VIP) — Intranasal spray, Subcutaneous injection, Inhalation (nebulized).
- Frequency: KPV is typically Once or twice daily; Vasoactive Intestinal Peptide (VIP) is Daily intranasal or 1–2x weekly subcutaneous.
- Research depth: this profile cites 3 sources for KPV vs 2 for Vasoactive Intestinal Peptide (VIP).
How each works
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
Vasoactive Intestinal Peptide (VIP)
VIP activates VPAC1 and VPAC2 receptors coupled to cAMP, suppressing pro-inflammatory cytokines while promoting Th2 regulatory immune responses and Treg differentiation. In the CIRS/biotoxin illness framework pioneered by Shoemaker, VIP intranasal formulation demonstrates normalization of inflammatory markers and improvement in TGF-β, MSH, and VIP deficiency seen in CIRS patients. Pulmonary vasodilation effects have been studied for PAH.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.